Brief: Ratos Company TFS HealthScience Supports Trial For Novel Vascular Therapy
29/05/2026 11:55
BRIEF-Ratos Company TFS HealthScience Supports Trial For Novel Vascular Therapy May 29 (Reuters) - Ratos AB RATOb.ST:
TFS HEALTHSCIENCE PARTNERS WITH VERIGRAFT FOR PHASE II/III P-TEV TRIAL
Source text: ID:nMFNbYcLHB
Further company coverage: [RATOb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Ratos AB
See all newsSweden's Ratos beats Q3 sales estimates
Brief: Ratos Reports Q3 Adjusted EBITA At SEK 480 Million
Brief: Ratos Q3 Sales SEK 4,427 Million Vs. IBES Estimate SEK 4,260 Million
Brief: Ratos's HL Display To Acquire Top Global
Brief: Ratos AB Q2 2026 Operating Profit Sek 1345M, Items Affecting Comparability Sek +387M